Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 16/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28598391 | 0.83 | ERN1 (0.44) | ERN1LMNAMAPTALDH1A1HPGD | |
| SCHEMBL24176913 | 0.83 | ERN1 (0.42) | ERN1LMNAMAPTALDH1A1HPGD | |
| SCHEMBL16978281 | 0.80 | ERN1 (0.51) | ERN1LMNAMAPTALDH1A1TLR2 | |
| SCHEMBL15535074 | 0.78 | ERN1 (0.49) | ERN1LMNAMAPTALDH1A1TLR2 | |
| SCHEMBL24176895 | 0.78 | LMNA (0.43) | ERN1LMNAMAPTALDH1A1HPGD | |
| SCHEMBL15535007 | 0.75 | ERN1 (0.59) | ERN1LMNAMAPTALDH1A1TLR2 | |
| SCHEMBL15547540 | 0.74 | ERN1 (0.62) | ERN1LMNAMAPTALDH1A1TLR2 | |
| SCHEMBL28675718 | 0.74 | ERN1 (0.50) | ERN1LMNAMAPTTLR2TLR1 | |
| SCHEMBL7409495 | 0.74 | ERN1 (0.46) | ERN1LMNAMAPTALDH1A1 | |
| SCHEMBL7417469 | 0.74 | ERN1 (0.48) | ERN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002232-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | ORION CORPORATION (FI) | 2022-01-06 | — | — | US | claimed |
| EP-3877360-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | Orion Corporation (FI) | 2021-09-15 | — | — | EP | claimed |
| CN-113166042-A | Method for preparing 4, 5-dihydroxy-2- (4-methylbenzyl) isophthalonitrile | 奥赖恩公司 | 2021-07-23 | — | — | CN | claimed |
| US-20220002232-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | ORION CORPORATION (FI) | 2022-01-06 | — | — | US | disclosed |
| US-20220002232-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | ORION CORPORATION (FI) | 2022-01-06 | — | — | US | disclosed |
| US-20220002232-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | ORION CORPORATION (FI) | 2022-01-06 | — | — | US | disclosed |
| EP-3877360-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | Orion Corporation (FI) | 2021-09-15 | — | — | EP | disclosed |
| EP-3877360-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | Orion Corporation (FI) | 2021-09-15 | — | — | EP | disclosed |
| CN-113166042-A | Method for preparing 4, 5-dihydroxy-2- (4-methylbenzyl) isophthalonitrile | 奥赖恩公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166042-A | Method for preparing 4, 5-dihydroxy-2- (4-methylbenzyl) isophthalonitrile | 奥赖恩公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020094928-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | ORION CORPORATION (FI) | 2020-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002232-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIHYDROXY-2-(4-METHYLBENZYL)ISOPHTHALONITRILE | COMT, DDT, HPD | ERN1 4520/4885LMNA 3433/4885MAPT 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.